Patents by Inventor Dan Samuel Kaufman

Dan Samuel Kaufman has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20200017570
    Abstract: This disclosure describes, generally, a modified form of CD16, genetically-modified cells that express the modified CD16, and methods that involve the genetically-modified cells. The modified form of CD16 can exhibit increased anti-tumor and/or anti-viral activity due, at least in part, to reduced susceptibility to ADAM17-mediated shedding upon NK cell stimulation.
    Type: Application
    Filed: September 19, 2019
    Publication date: January 16, 2020
    Inventors: Bruce Kenneth Walcheck, Dan Samuel Kaufman, Jianming Wu, Yawu Jing, Zhenya Ni
  • Patent number: 10464989
    Abstract: This disclosure describes, generally, a modified form of CD 16, genetically-modified cells that express the modified CD 16, and methods that involve the genetically-modified cells. The modified form of CD 16 can exhibit increased anti-tumor and/or anti- viral activity due, at least in part, to reduced susceptibility to ADAM17-mediated shedding upon NK cell stimulation.
    Type: Grant
    Filed: March 27, 2015
    Date of Patent: November 5, 2019
    Assignee: Regents of the University of Minnesota
    Inventors: Bruce Kenneth Walcheck, Dan Samuel Kaufman, Jianming Wu, Yawu Jing, Zhenya Ni
  • Publication number: 20180002438
    Abstract: This disclosure describes chimeric antigen receptors for expression in a Natural Killer (NK) cell, pharmaceutical compositions that include NK cells (and/or iPSCs) modified to express a chimeric antigen receptor, and methods involving such chimeric antigen receptors. Generally, the chimeric antigen receptor includes an ectodomain that includes an antigen recognition region, a transmembrane domain linked to the ectodomain, and an endodomain linked to the transmembrane domain. The endodomain can include a signaling peptide that activates an NK cell.
    Type: Application
    Filed: January 28, 2016
    Publication date: January 4, 2018
    Inventors: Dan Samuel KAUFMAN, David Lee LAMPI HERMANSON, Branden Scott MORIARITY
  • Publication number: 20170174743
    Abstract: This disclosure describes, generally, a modified form of CD 16, genetically-modified cells that express the modified CD 16, and methods that involve the genetically-modified cells. The modified form of CD 16 can exhibit increased anti-tumor and/or anti- viral activity due, at least in part, to reduced susceptibility to ADAM17-mediated shedding upon NK cell stimulation.
    Type: Application
    Filed: March 27, 2015
    Publication date: June 22, 2017
    Inventors: Bruce Kenneth Walcheck, Dan Samuel Kaufman, Jianming Wu, Yawu Jing, Zhenya Li
  • Publication number: 20170121683
    Abstract: Methods for enhancing and disrupting activity of the aryl hydrocarbon receptor (AHR) and cells having disrupted or enhanced AHR activity. The methods and cells may be used to enhance production of specific cell populations during hemato-endothelial cell or hemato-lymphoid cell development.
    Type: Application
    Filed: November 3, 2016
    Publication date: May 4, 2017
    Inventors: Dan Samuel Kaufman, Mathew George Angelos